Development of an automated and High throughput UHPLC/MS based workflow for cleaning verification of potent compounds in the pharmaceutical manufacturing environment.


Journal

Journal of pharmaceutical and biomedical analysis
ISSN: 1873-264X
Titre abrégé: J Pharm Biomed Anal
Pays: England
ID NLM: 8309336

Informations de publication

Date de publication:
05 Sep 2020
Historique:
received: 24 03 2020
revised: 05 05 2020
accepted: 29 05 2020
pubmed: 21 6 2020
medline: 22 6 2021
entrez: 21 6 2020
Statut: ppublish

Résumé

Cleaning verification (CV) is a critical step in the pharmaceutical manufacturing process to eliminate or reduce unacceptable contamination of a product as a result of insufficiently cleaned equipment surfaces. The main concern is cross contamination with active pharmaceutical ingredients (APIs) from previous runs that may impact patient safety. Current conventional approaches involve rather tedious sample preparation and analytical methods with relative lengthy analysis time. Potent APIs possessing low acceptable daily intake (ADI) values require analytical methods for CV with very low detection limits to confirm that these APIs are below their acceptance limits prior to the next manufacturing process. In this work, a novel end to end CV workflow was developed, which includes the automated sample and calibration solution preparation as well as high throughput analysis by ultra-high-performance liquid chromatography (UHPLC) coupled with single quadrupole mass spectrometry in multiple injection chromatography and selected ion monitoring mode (MIC-MS-SIM). The method was validated using ten model compounds. Acceptable specificity, linearity (R

Identifiants

pubmed: 32563056
pii: S0731-7085(20)31287-5
doi: 10.1016/j.jpba.2020.113401
pii:
doi:

Substances chimiques

Pharmaceutical Preparations 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

113401

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Huaming Sheng (H)

Analytical Science, Merck & Co., Inc., Rahway, New Jersey 07065, United States. Electronic address: huaming.sheng@merck.com.

Dae Kim (D)

Analytical Science, Merck & Co., Inc., Rahway, New Jersey 07065, United States.

Alexander S Chin (AS)

Preformulation, Merck & Co., Inc., Rahway, New Jersey 07065, United States.

Yuejie Zhao (Y)

Analytical Science, Merck & Co., Inc., Rahway, New Jersey 07065, United States.

Yong Liu (Y)

Analytical Science, Merck & Co., Inc., Rahway, New Jersey 07065, United States.

Ravi Katwaru (R)

Pharmacokinetics,Pharmacodynamics, & Drug Metabolism, Merck & Co., Inc., West Point, Pennsylvania, 19486, United States.

Kevin P Bateman (KP)

Pharmacokinetics,Pharmacodynamics, & Drug Metabolism, Merck & Co., Inc., West Point, Pennsylvania, 19486, United States.

Andreas Abend (A)

Analytical Science, Merck & Co., Inc., Rahway, New Jersey 07065, United States.

W Peter Wuelfing (WP)

Analytical Science, Merck & Co., Inc., Rahway, New Jersey 07065, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH